Celcuity (CELC) Stock Forecast & Price Target

Celcuity is supported by a compelling commercial and clinical setup, as REVTORPYK launched on September 30, 2026 with early access already broad: 78% of the top 36 strategic accounts have ordered, 91% of U.S. commercial and Medicare lives are covered, and more than 3,400 sites have engaged. The fundamental thesis is reinforced by differentiated phase 3 data showing gedatolisib’s broad activity across PIK3CA wild-type and mutant disease, including 9.3 months mPFS in wild-type patients and 11.1 to 11.3 months in mutant patients versus 5.6 months for alpelisib plus fulvestrant. Financially, the company reported a 3Q26 GAAP net loss of $1.33 per share and ended the quarter with $642.7 million in cash, cash equivalents and short-term investments, which management expects to fund operations through 2029.

Celcuity is fundamentally a high-risk, capital-intensive biotech with a single lead asset, so the investment case depends heavily on gedatolisib succeeding across multiple indications while the company still faces FDA, regulatory, and commercial execution risk. Even with Phase 3 VIKTORIA-1 enrollment completed and PIK3CA WT results reported, the path to broad adoption remains uncertain because weekly IV administration, stomatitis, and buy-and-bill reimbursement friction can slow uptake, while its sole production site creates manufacturing vulnerability. The competitive bar is also steep in HR+/HER2- breast cancer, where existing CDK4/6 inhibitor plus aromatase inhibitor regimens show median PFS of 25-28 months and oral rivals may win on convenience, limiting Celcuity’s ability to convert clinical activity into durable revenue.